跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NUCALA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NUCALA
Authorized
STANDARD
NUCALA
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
d47f544e5f8f1ed6
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
d47f544e5f8f1ed6
Drug Approval Canada Name
NUCALA
Product Name
NUCALA
Status
Cancelled Post Market
Status Date
2023-12-06
Original Market Date
2016-03-14
Din
02449781
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
90:28.00
Atc Original
R03DX09 MEPOLIZUMAB
Atc Name
r 03 dx 09
Aig Number
0157630001
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc.
Name En
GlaxoSmithKline Inc.
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
MEPOLIZUMAB
100 MG / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
d47f544e5f8f1ed6
Type
Standard
Back to Health Canada Approvals